In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Arbutus Biopharma Corp (NASDAQ: ABUS) closed at $3.37 in the last session, down -2.03% from day before closing price of $3.44. In other words, the price has decreased by -$2.03 from its previous closing price. On the day, 1.39 million shares were traded.
Ratios:
We take a closer look at ABUS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.02 and its Current Ratio is at 7.02. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 04 ’25 when HASTINGS DAVID C sold 22,183 shares for $3.28 per share. The transaction valued at 72,827 led to the insider holds 159,724 shares of the business.
Sims Karen sold 19,348 shares of ABUS for $63,519 on Feb 04 ’25. The Chief Medical Officer now owns 106,194 shares after completing the transaction at $3.28 per share. On Feb 04 ’25, another insider, McElhaugh Michael J., who serves as the Interim President & CEO of the company, sold 23,790 shares for $3.28 each. As a result, the insider received 78,103 and left with 1,481,003 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 94.75 while its Price-to-Book (P/B) ratio in mrq is 5.97.
Stock Price History:
Over the past 52 weeks, ABUS has reached a high of $4.72, while it has fallen to a 52-week low of $2.30. The 50-Day Moving Average of the stock is 1.32%, while the 200-Day Moving Average is calculated to be -5.73%.
Shares Statistics:
A total of 189.44M shares are outstanding, with a floating share count of 147.08M. Insiders hold about 22.38% of the company’s shares, while institutions hold 54.97% stake in the company.
Earnings Estimates
The current rating of Arbutus Biopharma Corp (ABUS) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.1 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.53 and -$0.57 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.47, with 4.0 analysts recommending between -$0.42 and -$0.6.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $2.21M. It ranges from a high estimate of $2.88M to a low estimate of $1.81M. As of the current estimate, Arbutus Biopharma Corp’s year-ago sales were $2.91MFor the next quarter, 5 analysts are estimating revenue of $1.98M. There is a high estimate of $2.24M for the next quarter, whereas the lowest estimate is $1.81M.
A total of 5 analysts have provided revenue estimates for ABUS’s current fiscal year. The highest revenue estimate was $9.66M, while the lowest revenue estimate was $8.21M, resulting in an average revenue estimate of $8.73M. In the same quarter a year ago, actual revenue was $24.63MBased on 5 analysts’ estimates, the company’s revenue will be $7.32M in the next fiscal year. The high estimate is $8.46M and the low estimate is $5.33M.
